Teva Pharmaceutical Industries (TEVA) Deferred Taxes (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Deferred Taxes for 18 consecutive years, with -$22.0 million the latest figure, recorded in Q1 2026.

• Quarterly Deferred Taxes fell 178.57% year-over-year to -$22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$721.0 million (down 72.9% YoY) and the FY2025 annual result came in at -$671.0 million, down 5.84% from the prior year.
• Deferred Taxes rose to -$22.0 million in Q1 2026 per TEVA's latest filing, from -$595.0 million in the prior quarter.
• Over the last five years, Deferred Taxes for TEVA reached as high as $150.0 million in Q4 2022 and fell as low as -$1.1 billion in Q2 2022.
• A 5-year average of -$159.3 million and a median of -$53.0 million in 2024 frame the typical range for Deferred Taxes.
• The largest YoY upside for Deferred Taxes was 450.0% in 2022 against a maximum downside of 6868.75% in 2022.
• Year by year, Deferred Taxes stood at $150.0 million in 2022, then plunged by 78.67% to $32.0 million in 2023, then changed by 0.0% to $32.0 million in 2024, then slumped by 1959.38% to -$595.0 million in 2025, then jumped by 96.3% to -$22.0 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered -$22.0 million, -$595.0 million, and $107.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.